Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Webinar on Gastric Cancer

Start date
23 Nov 2021
End date
23 Nov 2021

Optimising sequential therapy in advanced gastric/GEJ cancer: the importance of appropriate treatment selection to improve treatment outcomes

In this webinar, the panel will review and discuss incorporation of immune checkpoint inhibitors in both first-line treatment for advanced disease and in the adjuvant setting, their impact on subsequent treatment, the current status of targeted therapy and the testing of biomarkers and upcoming combination treatment strategies in patients with gastric/GEJ cancer.


This webinar is part of the ESMO Asia Virtual Oncology Week 2021 (#ESMOasiaweek21), taking place on 17-23 November, and presenting the most important innovations in cancer research and care in 2021, highlighting Asian studies with a strong impact on the science and practice of oncology. Participation is free of charge.


Ian Chau


Markus Moehler, Hanneke van Laarhoven, Takako Nakajima


  • Welcome and Introduction, Prof. Ian Chau, Royal Marsden Hospital, Institute of Cancer Research, London & Surrey, UK
  • Incorporating checkpoint inhibitors into early line therapy and its impact on subsequent treatment in gastric/GEJ adenocarcinoma, Prof. Dr. Markus Moehler, MD, Head of GI Oncology, Senior Physician Gastroenterology & Endosonography at Mainz University, Mainz, Germany
  • Which, when and how to test for biomarkers in targeted therapy in gastric cancers: HER2 and beyond, Prof. Hanneke van Laarhoven, Head of the Department of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, Netherlands
  • Combination strategies: moving IO forward in gastric cancer, Prof. Takako Nakajima, MD, PhD, Department of Early Clinical Development, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • Clinical cased based discussion: Q&A,  
  • Conclusions and perspectives, Prof. Ian Chau, Royal Marsden Hospital, Institute of Cancer Research, London & Surrey, UK

Learning objectives

  • To understand the current paradigm of incorporating checkpoint inhibitors both in the first line advanced disease and post-operative adjuvant settings and its impact on subsequent treatment in gastric/GEJ adenocarcinoma
  • To review the current status of HER2 and other targeted therapy and understand when and how to test for these biomarkers in the patient’s treatment pathway
  • To appreciate the upcoming strategies of improving on immunotherapy in gastric cancer
  • To review the above objectives via a short clinical cased discussion as well as audience Q&A session.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.